Book contents
- Cambridge Textbook Of Neuroscience for Psychiatrists
- Reviews
- Cambridge Textbook of Neuroscience for Psychiatrists
- Copyright page
- Contents
- Contributors
- Introduction
- 1 Cells
- 2 Neurotransmitters and Receptors
- 3 Basic Techniques in Neuroscience
- 4 Neuroanatomy
- 5 Neural Circuits
- 6 Modulators
- 6.1 The Hypothalamic–Pituitary (Neuroendocrine) Axis
- 6.2 The Stress Response and Glucocorticoids
- 6.3 Adrenal Steroids
- 6.4 Inflammation and Immune Responses
- 7 Genetics
- 8 Neurodevelopment and Neuroplasticity
- 9 Integrated Neurobiology of Specific Syndromes and Treatments
- 10 Neurodegeneration
- Index
- References
6.1 - The Hypothalamic–Pituitary (Neuroendocrine) Axis
from 6 - Modulators
Published online by Cambridge University Press: 08 November 2023
Book contents
- Cambridge Textbook Of Neuroscience for Psychiatrists
- Reviews
- Cambridge Textbook of Neuroscience for Psychiatrists
- Copyright page
- Contents
- Contributors
- Introduction
- 1 Cells
- 2 Neurotransmitters and Receptors
- 3 Basic Techniques in Neuroscience
- 4 Neuroanatomy
- 5 Neural Circuits
- 6 Modulators
- 6.1 The Hypothalamic–Pituitary (Neuroendocrine) Axis
- 6.2 The Stress Response and Glucocorticoids
- 6.3 Adrenal Steroids
- 6.4 Inflammation and Immune Responses
- 7 Genetics
- 8 Neurodevelopment and Neuroplasticity
- 9 Integrated Neurobiology of Specific Syndromes and Treatments
- 10 Neurodegeneration
- Index
- References
Summary
Although the term neuroendocrine is now applied to many different contexts in which the nervous system interacts with the endocrine system to regulate hormone release and bring about important changes in physiology, the hypothalamic–pituitary axis remains the best known and most well-characterised example of a neuroendocrine system. Here, the hypothalamus acts as the major coordinating centre, integrating a diverse array of intrinsic (e.g. higher cortical, autonomic, endocrine) and extrinsic (e.g. environmental) signals to direct the function of multiple different target cells/tissues within the central nervous system, pituitary gland and peripheral sites. Hypothalamic regulation of pituitary function has far-reaching consequences, governing the release of hormones from other key endocrine glands (e.g. adrenal, thyroid, gonad), which, in turn, regulate the function of many physiological pathways with important consequences for energy balance and metabolism, osmo- and thermo-regulation, heart rate and blood pressure control, central nervous system function, growth and reproduction.
- Type
- Chapter
- Information
- Cambridge Textbook of Neuroscience for Psychiatrists , pp. 287 - 299Publisher: Cambridge University PressPrint publication year: 2023
References
Bergthorsdottir, R, Leonsson-Zachrisson, M, Odén, A, Johannsson, G. Premature mortality in patients with Addison’s disease: a population-based study. J Clin Endocrinol Metab 2006; 91(12): 4849–4853.CrossRefGoogle ScholarPubMed
Simpson, H, Tomlinson, J, Wass, J, Dean, J, Arlt, W. Guidance for the prevention and emergency management of adult patients with adrenal insufficiency. Clin Med 2020; 20(4): 371.CrossRefGoogle ScholarPubMed
Gurnell, M, Heaney, LG, Price, D, Menzies‐Gow, A. Long‐term corticosteroid use, adrenal insufficiency, and the need for steroid‐sparing treatment in adult severe asthma. J Intern Med 2021; 290(2): 240–256.CrossRefGoogle ScholarPubMed
Øksnes, M, Bensing, S, Hulting, A-L et al. Quality of life in European patients with Addison’s disease: validity of the disease-specific questionnaire AddiQoL. J Clin Endocrinol Metab 2012; 97(2): 568–576.CrossRefGoogle ScholarPubMed
Kelly, W. Psychiatric aspects of Cushing’s syndrome. QJM Int J Med 1996; 89(7): 543–552.CrossRefGoogle ScholarPubMed
Starkman, MN, Schteingart, DE. Neuropsychiatric manifestations of patients with Cushing’s syndrome: relationship to cortisol and adrenocorticotropic hormone levels. Arch Intern Med 1981;141(2): 215–219.CrossRefGoogle ScholarPubMed
Starkman, MN, Gebarski, SS, Berent, S, Schteingart, DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry 1992; 32(9): 756–765.CrossRefGoogle ScholarPubMed
Pivonello, R, Simeoli, C, De Martino, MC et al. Neuropsychiatric disorders in Cushing’s syndrome. Front Neurosci 2015; 9: 129.CrossRefGoogle ScholarPubMed
Milian, M, Teufel, P, Honegger, J. The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD‐25). Part I: construction and psychometric properties. Clin Endocrinol (Oxf) 2012; 76(6): 851–860.CrossRefGoogle ScholarPubMed
Cusimano, MD, Huang, TQ, Marchie, A, Smyth, HS, Kovacs, K. Development and validation of the disease-specific QOL-CD quality of life questionnaire for patients with Cushing’s disease. Neurosurg Focus 2020; 48(6): E4.CrossRefGoogle ScholarPubMed
Demet, MM, Özmen, B, Deveci, A et al. Depression and anxiety in hyperthyroidism. Arch Med Res 2002; 33(6): 552–556.CrossRefGoogle ScholarPubMed
Suwalska, A, Lacka, K, Lojko, D, Rybakowski, J. Quality of life, depressive symptoms and anxiety in hyperthyroid patients. Rocz Akad Med W Bialymstoku 2005; 50: 61–63.Google ScholarPubMed
Bunevicius, R, Prange, AJ. Psychiatric manifestations of Graves’ hyperthyroidism. CNS Drugs 2006; 20(11): 897–909.CrossRefGoogle ScholarPubMed
Trivalle, C, Doucet, J, Chassagne, P et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 1996; 44(1): 50–53.CrossRefGoogle ScholarPubMed
Samuels, MH, Schuff, KG, Carlson, NE, Carello, P, Janowsky, JS. Health status, psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. Thyroid 2007; 17(3): 249–258.CrossRefGoogle ScholarPubMed
Samuels, MH. Psychiatric and cognitive manifestations of hypothyroidism. Curr Opin Endocrinol Diabetes Obes 2014; 21(5): 377.CrossRefGoogle ScholarPubMed
Bauer, M, Berman, S, Stamm, T et al. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. Mol Psychiatry 2016; 21(2): 229–236.CrossRefGoogle ScholarPubMed
Stamm, TJ, Lewitzka, U, Sauer, C et al. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014; 75(2): 162–168.CrossRefGoogle ScholarPubMed
Huisman, J, Bosch, J, Waal, HD-V. Personality development of adolescents with hypogonadotropic hypogonadism. Psychol Rep 1996; 79(3_suppl): 1123–1126.CrossRefGoogle ScholarPubMed
Degerblad, M, Almkvist, O, Grunditz, R et al. Physical and psychological capabilities during substitution therapy with recombinant growth hormone in adults with growth hormone deficiency. Eur J Endocrinol 1990; 123(2): 185–193.CrossRefGoogle ScholarPubMed
McKenna, SP, Doward, LC, Alonso, J et al. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999; 8(4): 373–383.CrossRefGoogle ScholarPubMed
Sartorio, A, Molinari, E, Riva, G et al. Growth hormone treatment in adults with childhood onset growth hormone deficiency: effects on psychological capabilities. Horm Res Paediatr 1995; 44(1): 6–11.CrossRefGoogle ScholarPubMed
McMillan, C, Bradley, C, Gibney, J, Healy, M, Russell‐Jones, D, Sönksen, P. Psychological effects of withdrawal of growth hormone therapy from adults with growth hormone deficiency. Clin Endocrinol (Oxf) 2003; 59(4): 467–475.CrossRefGoogle ScholarPubMed
Webb, S, Prieto, L, Badia, X et al. Acromegaly Quality of Life Questionnaire (ACROQOL), a new health‐related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 2002; 57(2): 251–258.CrossRefGoogle ScholarPubMed
Sievers, C, Dimopoulou, C, Pfister, H et al. Prevalence of mental disorders in acromegaly: a cross‐sectional study in 81 acromegalic patients. Clin Endocrinol (Oxf) 2009; 71(5): 691–701.CrossRefGoogle ScholarPubMed
Szcześniak, D, Jawiarczyk-Przybyłowska, A, Rymaszewska, J. The quality of life and psychological, social and cognitive functioning of patients with acromegaly. Adv Clin Exp Med Off Organ Wroclaw Med Univ 2015; 24(1): 167.CrossRefGoogle ScholarPubMed
Sibeoni, J, Manolios, E, Verneuil, L, Chanson, P, Revah-Levy, A. Patients’ perspectives on acromegaly diagnostic delay: a qualitative study. Eur J Endocrinol 2019; 180(6): 339–352.CrossRefGoogle ScholarPubMed
Wolters, TLC, Roerink, SH, Sterenborg, R et al. The effect of treatment on quality of life in patients with acromegaly: a prospective study. Eur J Endocrinol 2020; 182(3): 319–331.CrossRefGoogle ScholarPubMed
Gorvin, CM. The prolactin receptor: diverse and emerging roles in pathophysiology. J Clin Transl Endocrinol 2015; 2(3): 85–91.Google ScholarPubMed
De Bellis, A, Bizzarro, A, Pivonello, R, Lombardi, G, Bellastella, A. Prolactin and autoimmunity. Pituitary 2005; 8(1): 25–30.CrossRefGoogle ScholarPubMed
Gomes, J, Sousa, A, Lima, G. Hyperprolactinemia: effect on mood? Eur Psychiatry 2015; 30(S1): 1–1.CrossRefGoogle Scholar
Meaney, AM, O’Keane, V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci 2002; 71(9): 979–92.CrossRefGoogle ScholarPubMed
Ioachimescu, AG, Fleseriu, M, Hoffman, AR, Vaughan Iii, TB, Katznelson, L. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol 2019; 180(1): 31–40.CrossRefGoogle ScholarPubMed
Barake, M, Evins, AE, Stoeckel, L et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary 2014; 17(2): 150–156.CrossRefGoogle ScholarPubMed
Siegler, EL, Tamres, D, Berlin, JA, Allen-Taylor, L, Strom, BL. Risk factors for the development of hyponatremia in psychiatric inpatients. Arch Intern Med 1995; 155(9): 953–957.CrossRefGoogle ScholarPubMed
Albers, HE. The regulation of social recognition, social communication and aggression: vasopressin in the social behavior neural network. Horm Behav 2012; 61(3): 283–292.CrossRefGoogle ScholarPubMed